TheranosticTrials.org

Clinical Trial · NCT05175404

Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers

Overview

Determine the diagnostic value of 18F-PSMA-11 in patients with iodine refractory thyroid cancer.

Sponsor

University Hospital, Ghent

Phase

Phase 2

ClinicalTrials.gov

NCT05175404

Drug / Compound

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC

Eligibility

Inclusion

  • Subject should have a routine clinical 18F-FDG PET/CT performed within two months prior to the study scan.
  • Female patients should be either post-menopausal, surgically sterile, or using highly effective contraceptives (methods that can achieve a failure rate of less than 1%: combined hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence).
  • Subject is diagnosed with a histologically confirmed differentiated thyroid carcinoma, that is considered RAI refractory. There is evidence of persisting or recurrent disease, based on serum thyroglobulin levels and/or medical imaging.

Exclusion

  • Subject is potentially pregnant (urinary test can be performed in case of doubt) or breastfeeding.
  • Patient is mentally or legally incapacitated.
  • Patient has a known other active malignancy.